| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3dded61bd89f99900518597c0958b9a9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D237-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502 |
| filingDate |
2017-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7339d83e44c477e7b5257d5bcd0ff4af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee38aeddaa64c2eadb02db88a4f44357 |
| publicationDate |
2019-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-109563080-A |
| titleOfInvention |
The preparation method of olaparib |
| abstract |
Provided herein is the preparation of 4-[(3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one (Olapa Ni) and its intermediates of the new process and method. Olaparib is a poly ADP ribose polymerase (PARP) inhibitor that can be used to treat cancer. The benefits of the present disclosure include the use of less toxic compounds and improved yields. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112500379-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113720927-A |
| priorityDate |
2016-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |